Scribe Therapeutics(NASDAQ) SCTX

Scribe Therapeutics creates genetic medicines that target the root causes of disease. Its technology helps prevent heart conditions by adjusting how specific genes function. These treatments aim to replace daily pills with a single long-lasting intervention.

Tools for Gene Correction

• STX-1150: Clinical-stage epigenetic silencing therapy designed to lower cholesterol by repressing the PCSK9 gene without making permanent DNA sequence modifications.
• ELXR Platform: Proprietary technology for durable epigenetic silencing, which regulates gene activity rather than changing the physical genomic structure.
• XE Platform: Engineering system used for precision gene editing to develop therapies like STX-1200 for reducing lipoprotein(a) levels.
• STX-1400: Developmental program targeting the APOC3 gene to treat conditions caused by severely high triglyceride levels in the blood.

Partnerships and New Funding

• Established strategic collaborations with Eli Lilly and Sanofi to apply precision-engineered CRISPR technologies to therapeutic areas outside of cardiometabolic disease.
• Awarded approximately $25.7 million in multi-year grant funding from the California Institute for Regenerative Medicine in December 2025.
• Initiated a first-in-human Phase 1 clinical trial of STX-1150 in 2026 for adults with high cholesterol and increased cardiovascular risk.
• Completed an initial public offering in July 2026 that generated approximately $140.7 million in net proceeds.

Precision Engineering for Better Health

Scribe uses a proprietary approach called CRISPR by Design that combines machine learning with computational engineering to optimize genetic medicines. This method allows the company to create therapies tailored for specific diseases while avoiding permanent changes to a patient genetic code.

A Look at the Numbers

• Collaboration revenue was $1.9 million for the three-month period ended June 30, 2026, down 61% year over year.
• Net loss was $23.8 million for the six-month period ended June 30, 2026, up 79% year over year.
• Research and development expenses were $20.1 million for the six-month period ended June 30, 2026, down 33% year over year.
• The company held $43.0 million in cash, cash equivalents, and investments as of June 30, 2026.
• Accumulated deficit reached $181.5 million as of June 30, 2026.

Bottom Line

Scribe has transitioned from a research-focused startup to a clinical-stage biotechnology company with diverse platform technologies. Its focus on single-dose genetic interventions and strategic industry partnerships supports its goal of transforming chronic disease care.